CD4 Cell Response to 3 Doses of Subcutaneous Interleukin 2: Meta-analysis of 3 Vanguard Studies
Open Access
- 1 July 2004
- journal article
- clinical trial
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 39 (1) , 115-122
- https://doi.org/10.1086/421775
Abstract
Background. In advance of a large clinical end point trial evaluating the effectiveness of subcutaneous interleukin 2 (scIL-2) for treatment of patients with human immunodeficiency virus (HIV) infection, 3 identically designed Vanguard trials were conducted in Buenos Aires, Argentina; Bangkok, Thailand; and Houston, Texas. To more precisely quantitate the effect on CD4 cell response of 3 different doses of scIL-2 that were administered twice daily for 5 days every 8 weeks, the results of these 3 trials were pooled in a meta-analysis.Keywords
This publication has 9 references indexed in Scilit:
- The Evaluation of Subcutaneous Proleukin® (interleukin-2) in a Randomized International TrialControlled Clinical Trials, 2002
- Randomized, Open-Label Study of the Impact of Two Doses of Subcutaneous Recombinant Interleukin-2 on Viral Burden in Patients With HIV-1 Infection and CD4+ Cell Counts of ≥300/mm3: CPCRA 059JAIDS Journal of Acquired Immune Deficiency Syndromes, 2002
- Efficacy of Low‐Dose Intermittent Subcutaneous Interleukin (IL)–2 in Antiviral Drug–Experienced Human Immunodeficiency Virus–Infected Persons with Detectable Virus Load: A Controlled Study of 3 IL‐2 Regimens with Antiviral Drug TherapyThe Journal of Infectious Diseases, 2001
- A randomized, controlled 24-week study of intermittent subcutaneous interleukin-2 in HIV-1 infected patients in ThailandAIDS, 2000
- Immunologic and Virologic Effects of Subcutaneous Interleukin 2 in Combination With Antiretroviral TherapyJAMA, 2000
- A Randomized, Controlled, Phase II Trial Comparing Escalating Doses of Subcutaneous Interleukin‐2 plus Antiretrovirals versus Antiretrovirals Alone in Human Immunodeficiency Virus–Infected Patients with CD4+Cell Counts ⩾350/mm3The Journal of Infectious Diseases, 2000
- Comparison of subcutaneous and intravenous interleukin-2 in asymptomatic HIV-1 infection: a randomised controlled trialThe Lancet, 1999
- A Randomized Trial of High‐ versus Low‐Dose Subcutaneous Interleukin‐2 Outpatient Therapy for Early Human Immunodeficiency Virus Type 1 InfectionThe Journal of Infectious Diseases, 1999
- Interleukin-2: Inception, Impact, and ImplicationsScience, 1988